OneSkin—a skin longevity brand powered by biotech—received a $20 million Series A investment from growth equity firm Prelude Growth Partners.

Founded by a team of female PhD scientists, OneSkin focuses exclusively on extending “skinspan.” It’s the period when skin remains healthy and functional. OneSkin uses rigorous scientific research to target the underlying mechanisms of aging, not just surface appearance. Its approach centers around longevity science, particularly targeting senescent cells. These aging cells accumulate in skin over time and contribute to inflammation, collagen breakdown and visible signs of aging.

OneSkin’s proprietary peptide, OS-01, reportedly reduces the burden of these senescent cells. The peptide makes skin look and behave like younger skin, according to company executives.

OneSkin’s topical and supplement offerings attracted a passionate community of consumers and fans including Jennifer Aniston, Camila Alves McConaughey and Katy Perry.

The investment, completed last month, marks a significant milestone in the brand’s next chapter of growth.

Investing in Wellness

Prelude Growth Partners’ portfolio includes several female-founded companies. It proactively approached the brand with a desire to invest. OneSkin leveraged the opportunity to replace an early seed stage investor with a partner who could best support them in this next stage of growth.

“OneSkin’s cutting edge science, novel proprietary technology, leadership in skin longevity, and compelling brand are truly unique in the category,” said Alicia Sontag, co-founder and managing partner, Prelude Growth.

“We are extremely proud to have the opportunity to partner with Carolina, Alessandra and the team at OneSkin to support them in creating an iconic, powerhouse brand of the future,” she added.

This strategic investment underscores Prelude Growth’s belief in the long-term potential of skin longevity as a category and in OneSkin’s leadership at the forefront of this movement.

“We’re incredibly proud to welcome Prelude Growth Partners to the OneSkin family,” said Carolina Reis Oliveira, PhD, co-founder and CEO of OneSkin. “Their team’s expertise in building modern consumer brands and their enthusiasm for our science-driven approach made this a natural fit. We weren’t looking for new capital — but their passion and belief in our vision made this an opportunity to expand our resources and work alongside people we deeply admire. We got ourselves a dream team.”